These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32347291)

  • 1. Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling.
    Gao W; Guo N; Zhao S; Chen Z; Zhang W; Yan F; Liao H; Chi K
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32347291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling.
    Gao W; Guo N; Zhao S; Chen Z; Zhang W; Yan F; Liao H; Chi K
    Cell Stress Chaperones; 2020 Nov; 25(6):899-908. PubMed ID: 32519137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.
    Liu Y; Li S; Gao Z; Li S; Tan Q; Li Y; Wang D; Wang Q
    Cardiovasc Toxicol; 2021 Aug; 21(8):655-668. PubMed ID: 34021461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KLK11 promotes the activation of mTOR and protein synthesis to facilitate cardiac hypertrophy.
    Wang Y; Liao H; Wang Y; Zhou J; Wang F; Xie Y; Zhao K; Gao W
    BMC Cardiovasc Disord; 2021 May; 21(1):266. PubMed ID: 34059001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mibefradil Alleviates High-Glucose-induced Cardiac Hypertrophy by Inhibiting PI3K/Akt/mTOR-mediated Autophagy.
    Zhao LG; Li PL; Dai Y; Deng JL; Shan MY; Chen B; Zhang KB; Guo SD; Xu ZH
    J Cardiovasc Pharmacol; 2020 Aug; 76(2):246-254. PubMed ID: 32433360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.
    Zhang Y; Shang Z; Liu A
    Amino Acids; 2021 Oct; 53(10):1533-1543. PubMed ID: 34494132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of relgulation of PPAR-α on cardiac hypertrophy and the relationship between the effect of PPAR-α with PI3K/Akt/mTOR pathway].
    Wu Y; Wang BX; Guo YY; Wang YQ
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2015 May; 31(3):284-8. PubMed ID: 26387199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the effective combinatorial components from Si-Miao-Yong-An decoction regarding the intervention on myocardial hypertrophy.
    Chen XY; Chen XH; Li L; Su CP; Zhang YL; Jiang YY; Guo SZ; Liu B
    J Ethnopharmacol; 2021 May; 271():113833. PubMed ID: 33465437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKD deletion promotes autophagy and inhibits hypertrophy in cardiomyocyte.
    Zhao D; Gao Y; Wang W; Pei H; Xu C; Zhao Z
    Exp Cell Res; 2020 Jan; 386(2):111742. PubMed ID: 31759056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuating PI3K/Akt- mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells.
    Magaye RR; Savira F; Hua Y; Xiong X; Huang L; Reid C; Flynn BL; Kaye D; Liew D; Wang BH
    Int J Biochem Cell Biol; 2021 May; 134():105952. PubMed ID: 33609744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats.
    Chen Y; Pan R; Zhang J; Liang T; Guo J; Sun T; Fu X; Wang L; Zhang L
    J Ethnopharmacol; 2021 May; 272():113920. PubMed ID: 33607200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiRNA-339-5p promotes isoproterenol-induced cardiomyocyte hypertrophy by targeting VCP to activate the mTOR signaling.
    Bi X; Zhang Y; Yu Y; Yuan J; Xu S; Liu F; Ye J; Liu P
    Cell Biol Int; 2022 Feb; 46(2):288-299. PubMed ID: 34854520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-17-5p Promotes Cardiac Hypertrophy by Targeting Mfn2 to Inhibit Autophagy.
    Xu X; Su YL; Shi JY; Lu Q; Chen C
    Cardiovasc Toxicol; 2021 Sep; 21(9):759-771. PubMed ID: 34120306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac-specific Traf2 overexpression enhances cardiac hypertrophy through activating AKT/GSK3β signaling.
    Huang Y; Wu D; Zhang X; Jiang M; Hu C; Lin J; Tang J; Wu L
    Gene; 2014 Feb; 536(2):225-31. PubMed ID: 24378234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways.
    Kang S; Chemaly ER; Hajjar RJ; Lebeche D
    J Biol Chem; 2011 May; 286(21):18465-73. PubMed ID: 21478152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes.
    Liu L; Zhao X; Pierre SV; Askari A
    Am J Physiol Cell Physiol; 2007 Nov; 293(5):C1489-97. PubMed ID: 17728397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KLF15 protects against isoproterenol-induced cardiac hypertrophy via regulation of cell death and inhibition of Akt/mTOR signaling.
    Gao L; Guo Y; Liu X; Shang D; Du Y
    Biochem Biophys Res Commun; 2017 May; 487(1):22-27. PubMed ID: 28336438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
    Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
    J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allicin attenuates pathological cardiac hypertrophy by inhibiting autophagy via activation of PI3K/Akt/mTOR and MAPK/ERK/mTOR signaling pathways.
    Ba L; Gao J; Chen Y; Qi H; Dong C; Pan H; Zhang Q; Shi P; Song C; Guan X; Cao Y; Sun H
    Phytomedicine; 2019 May; 58():152765. PubMed ID: 31005720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.
    Clemente CF; Xavier-Neto J; Dalla Costa AP; Consonni SR; Antunes JE; Rocco SA; Pereira MB; Judice CC; Strauss B; Joazeiro PP; Matos-Souza JR; Franchini KG
    J Mol Cell Cardiol; 2012 Feb; 52(2):493-501. PubMed ID: 22056317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.